RNA250117P39000
- 4.80
- 0.000.00%
Avidity Biosciences Newsroom
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Analysts Offer Insights on Healthcare Companies: NeuroPace (NPCE), Tecan Group AG (OtherTCHBF) and Avidity Biosciences (RNA)
Avidity Biosciences Plans to Submit First Biologics License Application This Year
Express News | Avidity Biosciences: Accelerated Approval Path Confirmed for Del-Zota; Bla Submission Planned for Year End 2025
Press Release: Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Companies Like Avidity Biosciences (NASDAQ:RNA) Are In A Position To Invest In Growth
H.C. Wainwright Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $72
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
What 8 Analyst Ratings Have To Say About Avidity Biosciences
Avidity Biosciences Initiated at Buy by HC Wainwright & Co.
Avidity Biosciences Price Target Announced at $72.00/Share by HC Wainwright & Co.
Avidity Biosciences Insider Sold Shares Worth $831,605, According to a Recent SEC Filing
PepGen Stock Craters 35% on FDA Clinical Hold
Avidity Biosciences (RNA) Receives a Buy From TD Cowen
Avidity Biosciences: Advancing Clinical Programs With Strategic Focus and Growth Potential
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Avidity Biosciences to Participate in Upcoming Investor Conference
RBC Capital Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $67
Express News | Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)